Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2017

Date: October 31, 2017
Pages: 78
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A5311FBC7B3EN
Leaflet:

Download PDF Leaflet

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2017
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2017, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline landscape.

Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. Predisposing factors include female, hereditary disease that affects the adrenal glands, age and smoking. Symptoms include high blood sugar and pressure, muscle weakness in the legs, excessive weight gain in chest and abdomen, early signs of puberty in children, increased facial and body hair, particularly in females and deepened voice in females.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development
AbbVie Inc
ArQule Inc
Exelixis Inc
Merck KGaA
Millendo Therapeutics Inc
Orphagen Pharmaceuticals Inc
Trovagene Inc
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Drug Profiles
8H-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABBV-176 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARQ-087 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATR-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avelumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PCM-075 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize SF-1 for Cushing's Syndrome, Endometriosis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones
Featured News & Press Releases
Mar 28, 2017: Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing's Syndrome
Mar 18, 2016: Millendo Therapeutics Announces Publication of Preclinical Data for ATR-101 and Data Presentations at ENDO 2016
Mar 03, 2015: Atterocor Announces Data Presentations at ENDO 2015
Dec 11, 2014: Atterocor Expands Phase 1 Trial of ATR-101 to Additional Leading Adrenal Cancer Centers
Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by AbbVie Inc, H2 2017
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by ArQule Inc, H2 2017
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Exelixis Inc, H2 2017
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck KGaA, H2 2017
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Millendo Therapeutics Inc, H2 2017
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Orphagen Pharmaceuticals Inc, H2 2017
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Trovagene Inc, H2 2017
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects, H2 2017
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

AbbVie Inc
ArQule Inc
Exelixis Inc
Merck KGaA
Millendo Therapeutics Inc
Orphagen Pharmaceuticals Inc
Trovagene Inc
Skip to top


Esophageal Cancer - Pipeline Review, H1 2017 US$ 2,000.00 Apr, 2017 · 493 pages
Nonmelanomatous Skin Cancer - Pipeline Review, H1 2015 US$ 2,000.00 Apr, 2015 · 44 pages
Uterine Cancer - Pipeline Review, H1 2014 US$ 2,000.00 Apr, 2014 · 50 pages

Ask Your Question

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: